Fig. 1

Oncomine disease summary for BRF2. Oncomine 4.5 was queried for (a) BRF2 expression in 715 data sets (83,733 samples) based on: cancer type, cancer versus normal, cancer versus cancer including histology and multi-cancer analysis types, and outlier analyses. Red shading of boxes denotes gene overexpression and blue shading represents decreased gene expression. The levels of expression are based on the gene rank percentile of 10%. This disease summary was performed using a criterion of a 2-fold change for gene expression and a p-value of 1E-4. BRF2 (a) is overexpressed in the following cancer vs normal data sets: breast, gastric, kidney, melanoma, and sarcoma cancers. In the cancer vs cancer data sets, BRF2 is overexpressed in kidney cancer (cancer histology data set), leukemia and lymphomas (multi-cancer) data sets. The outlier analysis demonstrates that BRF2 is both over- and under-expressed across the analyzed cancers. b Using the same stringent criterion, outlier analyses for estrogen receptor alpha (ER) (ESR1) and the progesterone receptor (PR), both categorized as biomarkers in breast cancer [30], were performed In addition, an Oncomine outlier analysis of TFIIB demonstrates over expression in 5 of 67 (0.07%) and underexpressed in 17 of 67 (25%) significant unique analyses of breast cancer data sets. The data sets analyzed during the current study are available at www.oncomine.org. Queries of Oncomine were performed in September 2019, October 2019, November 2019, January 2020, February 2020, and March 2020. (c) BRF2 is significantly overexpressed in Cho Gastric Stroma Data set [31], n = 80 samples and p = 9.965E-5. There is a 2.4-fold increase in BRF2 mRNA expression gastrointestinal stromal tumors as compared to controls. d BRF2 is significantly overexpressed in the TCGA Breast Cancer Data set [28], n = 593 samples and p = 9.34E-7. There is a 2.3-fold increase in BRF2 mRNA expression in Intraductal Cribriform Breast Adenocarcinoma, a form of invasive breast cancer, as compared to controls. The data sets analyzed during the current study are available at www.oncomine.org. Queries of Oncomine were performed in September 2019, October 2019, November 2019, January 2020, February 2020, and March 2020